Aumolertinib

Last updated

Aumolertinib
Aumolertinib.svg
Clinical data
Trade names Ameile
Other namesAlmonertinib; HS-10296
ATC code
Legal status
Legal status
  • CN: Rx-only
Identifiers
  • N-[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C30H35N7O2
Molar mass 525.657 g·mol−1
3D model (JSmol)
  • CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
  • InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
  • Key:DOEOECWDNSEFDN-UHFFFAOYSA-N

Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. [1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). [2]

Contents

In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy. [3] [4]

Society and culture

In December 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aumseqa, intended for the treatment of non-small cell lung cancer (NSCLC). [5] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH. [5]

References

  1. ↑ Shirley M, Keam SJ (April 2022). "Aumolertinib: A Review in Non-Small Cell Lung Cancer". Drugs. 82 (5): 577–584. doi:10.1007/s40265-022-01695-2. PMID   35305259.
  2. ↑ Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, et al. (2023). "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology. 41 (16) TPS9153. doi:10.1200/JCO.2023.41.16_suppl.TPS9153.
  3. ↑ "Almonertinib Approved in China for EGFR T79M+ NSCLC". onclive.com. 19 March 2020.
  4. ↑ Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. (March 2022). "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial". Journal of Thoracic Oncology. 17 (3): 411–422. doi: 10.1016/j.jtho.2021.10.024 . PMID   34801749.
  5. 1 2 "Aumseqa EPAR". European Medicines Agency (EMA). 12 December 2025. Retrieved 22 December 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.